Jackson SJ - Search Results

1

Cannabinoid control of neuroinflammation related to multiple sclerosis.

Baker D, Jackson SJ, Pryce G. Baker D, et al. Among authors: jackson sj. Br J Pharmacol. 2007 Nov;152(5):649-54. doi: 10.1038/sj.bjp.0707458. Epub 2007 Sep 24. Br J Pharmacol. 2007. PMID: 17891167 Free PMC article. Review.

2

Cannabinoids inhibit neurodegeneration in models of multiple sclerosis.

Pryce G, Ahmed Z, Hankey DJ, Jackson SJ, Croxford JL, Pocock JM, Ledent C, Petzold A, Thompson AJ, Giovannoni G, Cuzner ML, Baker D. Pryce G, et al. Among authors: jackson sj. Brain. 2003 Oct;126(Pt 10):2191-202. doi: 10.1093/brain/awg224. Epub 2003 Jul 22. Brain. 2003. PMID: 12876144

3

Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis.

Croxford JL, Pryce G, Jackson SJ, Ledent C, Giovannoni G, Pertwee RG, Yamamura T, Baker D. Croxford JL, et al. Among authors: jackson sj. J Neuroimmunol. 2008 Jan;193(1-2):120-9. doi: 10.1016/j.jneuroim.2007.10.024. Epub 2007 Nov 26. J Neuroimmunol. 2008. PMID: 18037503

4

Genetic background can result in a marked or minimal effect of gene knockout (GPR55 and CB2 receptor) in experimental autoimmune encephalomyelitis models of multiple sclerosis.

Sisay S, Pryce G, Jackson SJ, Tanner C, Ross RA, Michael GJ, Selwood DL, Giovannoni G, Baker D. Sisay S, et al. Among authors: jackson sj. PLoS One. 2013 Oct 9;8(10):e76907. doi: 10.1371/journal.pone.0076907. eCollection 2013. PLoS One. 2013. PMID: 24130809 Free PMC article.

5

Big conductance calcium-activated potassium channel openers control spasticity without sedation.

Baker D, Pryce G, Visintin C, Sisay S, Bondarenko AI, Vanessa Ho WS, Jackson SJ, Williams TE, Al-Izki S, Sevastou I, Okuyama M, Graier WF, Stevenson LA, Tanner C, Ross R, Pertwee RG, Henstridge CM, Irving AJ, Schulman J, Powell K, Baker MD, Giovannoni G, Selwood DL. Baker D, et al. Among authors: jackson sj. Br J Pharmacol. 2017 Aug;174(16):2662-2681. doi: 10.1111/bph.13889. Epub 2017 Jul 7. Br J Pharmacol. 2017. PMID: 28677901 Free PMC article. Clinical Trial.

6

Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation.

Jackson SJ, Pryce G, Diemel LT, Cuzner ML, Baker D. Jackson SJ, et al. Neuroscience. 2005;134(1):261-8. doi: 10.1016/j.neuroscience.2005.02.045. Neuroscience. 2005. PMID: 15953683

7

Neurofilament a biomarker of neurodegeneration in autoimmune encephalomyelitis.

Gnanapavan S, Grant D, Pryce G, Jackson S, Baker D, Giovannoni G. Gnanapavan S, et al. Autoimmunity. 2012 Jun;45(4):298-303. doi: 10.3109/08916934.2012.654865. Epub 2012 Feb 15. Autoimmunity. 2012. PMID: 22276904

8

Cannabinoid-mediated neuroprotection following interferon-gamma treatment in a three-dimensional mouse brain aggregate cell culture.

Jackson SJ, Baker D, Cuzner ML, Diemel LT. Jackson SJ, et al. Eur J Neurosci. 2004 Nov;20(9):2267-75. doi: 10.1111/j.1460-9568.2004.03711.x. Eur J Neurosci. 2004. PMID: 15525268

9

Cannabinoids and neuroprotection in CNS inflammatory disease.

Jackson SJ, Diemel LT, Pryce G, Baker D. Jackson SJ, et al. J Neurol Sci. 2005 Jun 15;233(1-2):21-5. doi: 10.1016/j.jns.2005.03.002. J Neurol Sci. 2005. PMID: 15894331 Review.

10

Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis.

Al-Izki S, Pryce G, Jackson SJ, Giovannoni G, Baker D. Al-Izki S, et al. Among authors: jackson sj. Mult Scler. 2011 Aug;17(8):939-48. doi: 10.1177/1352458511400476. Epub 2011 Apr 1. Mult Scler. 2011. PMID: 21459808

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

96 results

Search Page